Samrat Pharmachem schedules board meeting on 14 Aug 2026 to approve Q2 un‑audited results

What Samrat Pharmachem announced

Samrat Pharmachem Ltd. (BSE: 530125) filed a board‑meeting notice with the Bombay Stock Exchange on 30 June 2026. The notice states that the Board of Directors will convene on 14 August 2026 to consider and approve the un‑audited financial results for the quarter ended 30 June 2026. No quantitative financial data were included in the filing.

Board meeting details

• Date of meeting: 14 August 2026
• Filing date: 30 June 2026 (09:40 UTC)
• Purpose: Review and approve the unaudited results for Q2 FY 2026‑27 (quarter ending 30 June 2026).
• Agenda items: The notice mentions “inter alia” – meaning among other items – the approval of the unaudited results. No other agenda points are disclosed.

Un‑audited financial results – information disclosed

The filing is limited to the meeting intimation; it does not provide any figures such as revenue, profit before tax, net profit, earnings per share, or cash‑flow metrics for the quarter. Consequently, investors cannot assess the company’s performance from this notice alone. The results will become publicly available after the board’s approval, typically through a separate earnings release or filing.

Key facts at a glance

Why this matters for investors

The notice signals that Samrat Pharmachem is moving towards the formal disclosure of its Q2 2026‑27 performance. Approval of unaudited results is a standard procedural step before audited numbers are released. While the filing itself does not reveal the company’s financial health, the upcoming board meeting and subsequent earnings release will provide the data investors need to evaluate profitability, growth trends, and cash‑flow status. Until those numbers are disclosed, the impact on valuation remains uncertain.

The board meeting on 14 August 2026 will determine whether the unaudited results are approved for public release.

Conclusion

Samrat Pharmachem has formally announced a board meeting for mid‑August 2026 to approve its unaudited financial results for the quarter ended 30 June 2026. The current filing contains no financial figures, so investors must await the subsequent earnings release to gauge the company’s performance. The meeting date and agenda are now public, providing a timeline for when the detailed results are likely to be disclosed.